Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
Type:
Application
Filed:
May 23, 2014
Publication date:
November 13, 2014
Applicants:
Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de Paris
Abstract: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-Mycobacterium paratuberculosis antibodies; for in vitro detection or quantification of specific anti-Mycobacterium paratuberculosis antibodies in a biological sample.
Type:
Grant
Filed:
October 24, 2008
Date of Patent:
November 11, 2014
Assignees:
Institut National de la Sante et de la Recherche Medicale (Inserm), Institut National de la Recherche Agronomique, Institut Pasteur
Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.
Type:
Application
Filed:
December 17, 2012
Publication date:
November 6, 2014
Applicants:
CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: The present invention relates to agent selected from the group consisting of an anti-S100B antibody, an anti-S100B aptamer or an inhibitor of S100B gene expression for use in a method for reducing airway hyperresponse in a subject in need thereof. The present invention also relates to a method for determining whether a subject is at risk of having or developing an airway hyperresonse comprising determining the level of S100B protein in a biological sample obtained from said subject.
Type:
Application
Filed:
November 22, 2012
Publication date:
November 6, 2014
Applicants:
INSERM (INSTITUT NATIONAL DE LA SENTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE STRASBOURG, CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
Abstract: The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy.
Type:
Application
Filed:
December 14, 2011
Publication date:
October 30, 2014
Applicants:
Institut National de la Santé et de la Recherche Médicale (INSERM), INSTITUT PAOLI-CALMETTES, UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille II
Inventors:
Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
Abstract: The present invention relates to a new clonable label for Correlative Light and Electron Microscopy based on the combination of modified metallothionein and lanthanides.
Type:
Application
Filed:
November 27, 2012
Publication date:
October 30, 2014
Applicants:
Institut Curie, Inserm (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique
Inventors:
Nebraska Zambrano, Vincent Semetey, Sergio Marco
Abstract: An electrode device having an insertion part (12) adapted to be inserted into the suprachoroidal space of an eye so as to reach a service position, and an handling part (14) for manipulation of the electrode device, said electrode device comprising: —a support (25) having a distal part (31); —a set of wires (20) supported by said support and mobile between a retracted position in which said wires substantially extend along the support, and a deployed position in which respective parts of said wires, called “outside parts”, project from said distal part (31) of the support; —an electrically conductive element forming at least a portion of a said outside part or supported by a said outside part; —an electrical conductor (60) enabling, in said deployed position, an electrical connection between said electrically conductive element and an electrical generator; and —an actuator (16, 60) adapted for an operator to move the set of wires from said retracted position to said deployed position in said service position.
Type:
Application
Filed:
August 14, 2012
Publication date:
October 23, 2014
Applicant:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: The present invention relates to an injection device comprising: —a first support (14) having a cup-shaped first contact surface (18) intented to come into contact with a first region of an outside surface of an eye, —a set of at least four injection needles (17) in fluid communication with each other and protruding from said first contact surface (18) at respective insertion points (22) so that the distance between the distal end (26) of any of said injection needles to said first contact surface is between 0.6 mm and 1.3 mm, the insertion points of the injection needles on the first contact surface being spread on said first contact surface so that the diameter (D?) of the largest circle (C?) that it is possible to include completely in the convex surface (E) defined by said insertion points on a front view of said first contact surface, without any insertion point being included in said circle, is less than 8 mm.
Type:
Application
Filed:
August 14, 2012
Publication date:
October 23, 2014
Applicant:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: The present invention relates to methods for diagnosing and treating Myhre Syndrome. The invention provides a method for diagnosing or predicting Myhre Syndrome, or a risk of Myhre Syndrome, in a subject, which method comprises detecting a mutation in SMAD4 gene, as compared to a control population, wherein the presence of said mutation is indicative of Myhre Syndrome or of a risk of Myhre Syndrome. The present invention also relates to an inhibitor of the SMAD4-mediated TGF?/BMP signalling pathway for use in the treatment of Myhre Syndrome.
Type:
Application
Filed:
July 27, 2012
Publication date:
October 16, 2014
Applicants:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DESCARTES - PARIS V
Inventors:
Valérie Cormier-Daire, Carine Le Goff, Arnold Munnich
Abstract: The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals: (II); (III); (IV), (V), (VI) (VII) and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.
Type:
Application
Filed:
October 24, 2012
Publication date:
October 16, 2014
Applicants:
Universite de Droit et de la Sante de Lille 2, INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur de Lille
Inventors:
Benoit Deprez, Nicolas Willand, Marion Flipo, Matthieu Desroses, Alain Baulard, Florence Leroux
Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
Type:
Application
Filed:
March 12, 2014
Publication date:
October 16, 2014
Applicant:
Institut National De La Sante Et De La Recherche Medicale (INSERM)
Abstract: The present invention relates to a method for treating an ocular disease in a subject comprising the steps consisting of i) delivering a pharmaceutical composition formulated with a therapeutic nucleic acid of interest into the suprachoroidal space of the diseased eye and ii) exposing the region where the pharmaceutical composition was delivered to an electrical field.
Type:
Application
Filed:
August 14, 2012
Publication date:
October 16, 2014
Applicant:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
Type:
Application
Filed:
June 22, 2012
Publication date:
October 9, 2014
Applicants:
ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
Inventors:
Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
Type:
Grant
Filed:
February 15, 2013
Date of Patent:
October 7, 2014
Assignees:
Assitance Publique—Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Gustave-Roussy, Universite de Versailles—St Quentin en Yvelines, Universite Paris-Sud
Inventors:
William Vainchenker, Valérie Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
Type:
Grant
Filed:
May 25, 2011
Date of Patent:
October 7, 2014
Assignees:
Institut National de la Santé et de la Recherche Médicale (INSERM), Chu de Toulouse, Universite d'Aix-Marseille
Abstract: The invention concerns a biomarker for diagnosing or prognosing childhood Membranous Nephropathy (MN), said biomarker is (i) cationic Bovine Serum Albumin (BSA), and/or (ii) an antibody that binds to a polypeptide of sequence SEQ ID NO: 3. The invention further concerns an antibody or antibody fragment or a composition comprising such an antibody or antibody fragment, wherein said antibody or antibody fragment is specific to an amino acid sequence SEQ ID NO: 3. The invention also concerns a foodstuff likely to contain BSA or cow milk or cow milk extracts, wherein said foodstuff is depleted in BSA.
Type:
Application
Filed:
September 1, 2011
Publication date:
October 2, 2014
Applicant:
Institut National de la Sante et de la Recherche Medicate (INSERM)